AIM: This study aimed to assess the effectiveness of genotype-guided warfarin dosing. PATIENTS & METHODS: A total of 109 adults were randomized to receive initial dosing as determined by an algorithm containing genetic (VKORC1 and CYP2C9) plus clinical information or only clinical information. Primary end points were the number of anticoagulation visits and the time in therapeutic range (TTR) over 90 days. Secondary end points included time to therapeutic dose, International Normalized Ratios of >4, emergency visits, hospitalizations, hemorrhagic events, thrombotic events and mortality. RESULTS: Neither primary end point was significantly different between groups (anticoagulation visits: 6.96 vs 6.37, p = 0.51; TTR: 0.40 vs 0.43, p = 0.59). Fewer emergency visits, hospitalizations, major hemorrhagic events, thrombotic events and deaths occurred in the genetic plus clinical group than in the clinical only group, but these differences were not statistically significant. CONCLUSION:Genotype-guided dosing did not decrease the number of anticoagulation visits or improve TTR. Our trial was not powered to detect anything but large differences for utilization and health outcomes.
RCT Entities:
AIM: This study aimed to assess the effectiveness of genotype-guided warfarin dosing. PATIENTS & METHODS: A total of 109 adults were randomized to receive initial dosing as determined by an algorithm containing genetic (VKORC1 and CYP2C9) plus clinical information or only clinical information. Primary end points were the number of anticoagulation visits and the time in therapeutic range (TTR) over 90 days. Secondary end points included time to therapeutic dose, International Normalized Ratios of >4, emergency visits, hospitalizations, hemorrhagic events, thrombotic events and mortality. RESULTS: Neither primary end point was significantly different between groups (anticoagulation visits: 6.96 vs 6.37, p = 0.51; TTR: 0.40 vs 0.43, p = 0.59). Fewer emergency visits, hospitalizations, major hemorrhagic events, thrombotic events and deaths occurred in the genetic plus clinical group than in the clinical only group, but these differences were not statistically significant. CONCLUSION: Genotype-guided dosing did not decrease the number of anticoagulation visits or improve TTR. Our trial was not powered to detect anything but large differences for utilization and health outcomes.
Authors: Daniel E Jonas; Thomas Miller; Shana Ratner; Brooke McGuirt; Carol E Golin; Catherine Grodensky; Emily Sturkie; Jennifer Kinley; Maureen Dale; Michael Pignone Journal: J Healthc Qual Date: 2017 Jan/Feb Impact factor: 1.095
Authors: John Valgus; Kristin W Weitzel; Josh F Peterson; Daniel J Crona; Christine M Formea Journal: Am J Health Syst Pharm Date: 2019-04-08 Impact factor: 2.637
Authors: Letícia C Tavares; Nubia E Duarte; Leiliane R Marcatto; Renata A G Soares; Jose E Krieger; Alexandre C Pereira; Paulo Caleb Junior Lima Santos Journal: Eur J Clin Pharmacol Date: 2018-07-26 Impact factor: 2.953
Authors: Khagendra Dahal; Sharan P Sharma; Erik Fung; Juyong Lee; Jason H Moore; John N Unterborn; Scott M Williams Journal: Chest Date: 2015-09 Impact factor: 9.410
Authors: Nita A Limdi; Todd M Brown; Aditi Shendre; Nianjun Liu; Charles E Hill; Timothy M Beasley Journal: Pharmacogenet Genomics Date: 2017-10 Impact factor: 2.089
Authors: Gary Tse; Mengqi Gong; Guangping Li; Sunny Hei Wong; William K K Wu; Wing Tak Wong; Leonardo Roever; Alex Pui Wai Lee; Gregory Y H Lip; Martin C S Wong; Tong Liu Journal: Br J Clin Pharmacol Date: 2018-06-21 Impact factor: 4.335